secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2025-04-18T23:59:59+00:00
Accession:  0001213900-25-033366
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.03, 3.02, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius issues CEO super-voting stock to push 16M-to-250M share increase; quorum cut to 1/3
--------------------------------------------------------------------------------

- One share of Series A Preferred sold to CEO Leonard Mazur for $100 with 1B votes, valid only on proposed authorized share increase from 16M to 250M common shares.
- Board amended bylaws reducing stockholder meeting quorum from majority to one-third to avoid adjournment risk.
- Series A has no conversion, dividend, or liquidation rights; redeemed for $100 automatically after vote results announced.
- Special meeting called; preliminary proxy filed for shareholder vote on the authorized share increase.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025033366/0001213900-25-033366-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390025033366/ea0238657-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-033366

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer